

ASSIGNMENT

WHEREAS **Silvano BRIENZA**, residing at 22, rue Saint-Yves, 75014 Paris, France (the "Assignor"), is an inventor of certain new and useful inventions in **DOSING REGIMENS FOR TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA** (the "Inventions"), as set forth in international patent application No. PCT/EP2020/076994 filed on 25 September 2020, claiming priority of (i) US provisional patent application No. 62/905,703 filed on 25 September 2019, (ii) US provisional patent application No. 63/016,762 filed on 28 April 2020 and (iii) European patent application No. 20184601.1 filed on 7 July 2020 (all together the "Patent Applications");

WHEREAS **MED-ONCO PROFILE SARL**, organized under the laws of France and having its principal place of business at 22, rue Saint-Yves, 75014 Paris, France ("Med-Onco"), is the owner of the Assignor's rights in and to said Inventions and Patent Applications;

WHEREAS **DEBIOPHARM INTERNATIONAL SA**, organized under the laws of Switzerland and having its principal place of business at Forum "après-demain", chemin de Messidor 5-7, 1006 Lausanne, Switzerland (the "Assignee") is desirous of acquiring said Assignors' entire right and interest in and to said Inventions and Patent Applications and any other application for letters patent (the "Letters Patents") or patents (the "Patents") deriving from or claiming priority thereto, and in and to Letters Patent or Patents, in the United States of America, in the member states of the European Patent Organisation, or in any country in the world, to be obtained therefor and thereon;

WHEREAS the Assignee and Med-Onco entered into a consultancy agreement effective April 1, 2011, as amended (the "Consultancy Agreement") under which Med-Onco through the Assignor provides consultancy and advice services to the Assignee in oncology and under which Med-Onco irrevocably assigns to the Assignee all development and inventions created under such Consultancy Agreement by Med-Onco and/or the Assignor.

NOW, THEREFORE, for good and valuable consideration as defined in the Consultancy Agreement, the receipt of which is hereby acknowledged, the Assignor and Med-Onco have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, to the Assignee, its successors, legal representatives and assigns, said Assignor and Med-Onco's entire rights, title and interest in and to the Inventions, Patent Applications and applications for Letters Patent, and any and all Letters Patent or Patents in the United States of America, in the member states of the European Patent Organisation, and in all countries in the world which may be granted therefore and thereon, and in and to any and all conversions, divisions, continuations, and continuations-in-part of said Patent Applications, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by said Assignee, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the Assignor and Med-Onco, had this sale and assignment not been made,

AND for the same consideration, the Assignor and Med-Onco hereby covenant and agree to and with the Assignee, its successors, legal representatives and assigns, that, at the effective date of these presents, Med-Onco is the sole and lawful owner of said Assignors' entire right, title and interest in and to said Inventions and Patent Applications, and that the same are unencumbered and that Med-Onco have good and full right and lawful authority to sell and convey the same in the manner herein set forth,

AND for the same consideration, the Assignor and Med-Onco hereby covenant and agree to and with said Assignee, its successors, legal representatives and assigns, that the Assignor and Med-Onco will, whenever counsel of said Assignee, or the counsel of its successor, legal representatives or assigns, shall advise that any proceeding in connection with said Inventions, Patent Applications, or said application for Letters Patent, or any proceedings in connection with Letters Patent for said Inventions in any country, including interference proceedings, is lawful and desirable or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all act necessary or required to be done for the procurement, maintenance, enforcement and defence of Letters Patent for said Inventions, without charge to said Assignee, its successors, legal representatives and assigns, but at the cost and expense of said Assignee, its successors, legal representatives and assigns,

AND said Assignor and Med-Onco hereby authorize and request the competent authorities to grant and issue any and all such Letters Patent in any country throughout the world, to said Assignee as the Assignee of said inventions and the Letters Patent to be issued thereon for the sole use of said Assignee, its successors, legal representatives and assigns.

This Assignment is effective as of 25 September 2019.

Silvano BRIENZA

23/2/2021 | 21:17 CET

Date

DocuSigned by:



23/2/2021

F8CE438A1312473...

Signature

Place

MED-ONCO PROFILE SARL:

Anne Gabrielle FARNIER
Manager

17/2/2021 | 16:59 CET

Full name & Title

Date

DocuSigned by:



17/02/2021

C1DD20A50122489...

Signature

Place

DEBIOPHARM INTERNATIONAL SA

Vanessa CURRAT
General Counsel,
Senior Executive Director IP & Legal Affairs

15/2/2021 | 08:25 CET

Date

Full name & Title

DocuSigned by:
Vanessa Currat
34584E219A794EC
Signature

15/2/2021

Place

ASSIGNMENT

This ASSIGNMENT, by:

Sergio Adrian SZYLDERGEMAJN ALTMAN, residing at 10, Chemin des Hirondelles, 1162 St-Prex; Switzerland, and

Claudio ZANNA, residing at Avenue de La Harpe 49, 1007 Lausanne, Switzerland hereinafter referred to as the "Assignors", respectively, witnesseth:

WHEREAS said Assignors have invented certain new and useful inventions in **DOSING REGIMENS FOR TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA**, as set forth in international patent application No. PCT/EP2020/076994 filed on 25 September 2020, claiming priority of US provisional patent application No. 62/905,703 filed on 25 September 2019; US provisional patent application No. 63/016,762 filed on 28 April 2020 and European patent application No. 20184601.1 filed on 7 July 2020;

WHEREAS **DEBIOPHARM INTERNATIONAL SA**, organized under the laws of Switzerland and having its principal place of business at "Forum après-demain", Chemin Messidor 5-7, 1006 Lausanne, Switzerland (*hereinafter referred to as the "Assignee"*) is desirous of acquiring said Assignors' entire right and interest in and to said inventions and said patent applications and any other application for Letters Patent deriving from or claiming priority thereto, and in and to Letters Patent or Patents, in the United States of America, or in any country, to be obtained therefor and thereon:

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, said Assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, to said Assignee, its successors, legal representatives and assigns, said Assignors' entire right, title and interest in and to the above-mentioned inventions, patent applications and applications for Letters Patent, and any and all Letters Patent or Patents that may be granted therefor and thereon in the United States of America and in all countries, and in and to any and all conversions, divisions, continuations, and continuations-in-part of said applications, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property (the Paris Convention), the same to be held and enjoyed by said Assignee, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors, had this sale and assignment not been made,

AND for the same consideration, said Assignors hereby covenant and agree to and with said Assignee, its successors, legal representatives and assigns, that, at the effective date of these presents, said Assignors are the sole and lawful owners of said Assignors' entire right, title and interest in and to said inventions and patent applications above-mentioned, and that the same are unencumbered and that said Assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth,

AND for the same consideration, said Assignors hereby covenant and agree to and with said Assignee, its successors, legal representatives and assigns, that said Assignors will, whenever counsel of said Assignee, or the counsel of its successor, legal representatives or assigns, shall advise that any proceeding in connection with said inventions, patent applications, or said application for Letters Patent, or any proceedings in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all act necessary or required to be done for the procurement, maintenance, enforcement and defence of Letters Patent for said inventions, without charge to said Assignee, its

Attorney Docket Number: _____

successors, legal representatives and assigns, but at the cost and expense of said Assignee, its successors, legal representatives and assigns,

AND said Assignors hereby authorize and request the competent authorities to grant and issue any and all such Letters Patent in any country throughout the world, to said Assignee as the Assignee of said inventions and the Letters Patent to be issued thereon for the sole use of said Assignee, its successors, legal representatives and assigns.

This Assignment is effective as of 25 September 2019.

Witness(es):

Inventors:

Pamela Davidson

Sergio Adrian
SZYLDERGEMAJN
ALTMAN

19/1/2021 | 08:55 CET

Full name

Full name

Date

DocuSigned by:

Pamela Davidson

DocuSigned by:

Sergio Szyldergemajn

st-Prex

Signature

Signature

Place

Pamela Davidson

Claudio ZANNA

18/1/2021 | 17:58 CET

Full name

Full name

Date

DocuSigned by:

Pamela Davidson

DocuSigned by:

Claudio Zanna

Lausanne

Signature

Signature

Place

ASSIGNMENT

WHEREAS **PROF. JEAN BOURHIS**, residing at Route de Lavaux 43, 1802 Corseaux, Switzerland (the "**Assignor**"), is an inventor of certain new and useful inventions in **DOSING REGIMENS FOR TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA** (the "Inventions"), as set forth in international patent application No. PCT/EP2020/076994 filed on 25 September 2020, claiming priority of (i) US provisional patent application No. 62/905,703 filed on 25 September 2019, (ii) US provisional patent application No. 63/016,762 filed on 28 April 2020 and (iii) European patent application No. 20184601.1 filed on 7 July 2020 (all together the "Patent Applications");

WHEREAS **CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)**, organized under the laws of Switzerland and having its principal place of business at Rue du Bugnon 21, 1011 Lausanne, Switzerland ("**CHUV**"), is the owner by employment and by law of the Assignor's rights in and to said Inventions and Patent Applications;

WHEREAS **DEBIOPHARM INTERNATIONAL SA**, organized under the laws of Switzerland and having its principal place of business at Forum "après-demain", chemin de Messidor 5-7, 1006 Lausanne, Switzerland (the "**Assignee**") is desirous of acquiring CHUV's entire right and interest in and to said Inventions and Patent Applications and any other application for letters patent (the "Letters Patents") or patents (the "Patents") deriving from or claiming priority thereto, and in and to Letters Patent or Patents, in the United States of America, in the member states of the European Patent Organisation, or in any country in the world, to be obtained therefor and thereon;

WHEREAS, the CHUV and Assignor hereby confirm that Assignor has assigned, transferred and set over to the CHUV said Assignor entire rights, title and interest in and to the Inventions, Patent Applications and applications for Letters Patent, and any and all Letters Patent or Patents in all countries in the world.

WHEREAS the Assignee and CHUV entered into two consultancy agreements effective respectively on October 5, 2012 and on September 23, 2019 (the "Consultancy Agreements") under which the CHUV through the Assignor provides consulting, advice and assistance services to the Assignee in the field of oncology and radio-oncology and under which the CHUV irrevocably assigns to the Assignee all development and inventions created under such Consultancy Agreements by CHUV and/or the Assignor.

NOW, THEREFORE, for good and valuable consideration as defined in the Consultancy Agreements, the receipt of which is hereby acknowledged, the CHUV has sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, to the Assignee, its successors, legal representatives and assigns, said CHUV's entire rights, title and interest in and to the Inventions, Patent Applications and applications for Letters Patent, and any and all Letters Patent or Patents in the United States of America, in the member states of the European Patent Organisation, and in all countries in the world which may be granted therefore and thereon, and in and to any and all conversions, divisions, continuations, and continuations-in-part of said Patent Applications, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by said Assignee, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as

the same would have been held and enjoyed by the CHUV, had this sale and assignment not been made,

AND for the same consideration, the CHUV hereby covenant and agrees to and with the Assignee, its successors, legal representatives and assigns, that, at the effective date of these presents, CHUV is the sole and lawful owner of said Assignors' entire right, title and interest in and to said Inventions and Patent Applications, and that the same are unencumbered and that CHUV have good and full right and lawful authority to sell and convey the same in the manner herein set forth,

AND for the same consideration, the Assignor and CHUV hereby covenant and agree to and with said Assignee, its successors, legal representatives and assigns, that the Assignor and CHUV will, whenever counsel of said Assignee, or the counsel of its successor, legal representatives or assigns, shall advise that any proceeding in connection with said Inventions, Patent Applications, or said application for Letters Patent, or any proceedings in connection with Letters Patent for said Inventions in any country, including interference proceedings, is lawful or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful, sign all papers and documents, take all lawful oaths, and do all act necessary or required to be done for the procurement, maintenance, enforcement and defence of Letters Patent for said Inventions, without charge to said Assignee, its successors, legal representatives and assigns, but at the cost and expense of said Assignee, its successors, legal representatives and assigns,

AND said Assignor and CHUV hereby authorize and request the competent authorities to grant and issue any and all such Letters Patent in any country throughout the world, to said Assignee as the Assignee of said inventions and the Letters Patent to be issued thereon for the sole use of said Assignee, its successors, legal representatives and assigns.

This Assignment is effective as of 25 September 2019.

Prof. Jean BOURHIS

Signature

26.05.2021

Date

Lausanne

Place

CENTRE HOSPITALIER UNIVERSITAIRE
VAUDOIS:

Prof. Philippe ECKERT
Managing Director

Full name & Title

Signature

02/03/2021

Date

Lausanne

Place

CENTRE HOSPITALIER UNIVERSITAIRE
VAUDOIS:

Dr. Stefan KOHLER
Director of PACTT

Full name & Title

26.05.2021
Date

S. Kohler
Signature

Lausanne
Place

DEBIOPHARM INTERNATIONAL SA

Vanessa CURRAT
General Counsel,
Senior Executive Director IP & Legal Affairs

Full name & Title

31.05.2021
Date

[Signature]
Signature

Lausanne
Place